Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin

Biochemical and Biophysical Research Communications

Volumn 348, Issue 1, 2006, Pages 139-144

  Paeshuyse, Jan ^a   Coelmont, Lotte ^a   Vliegen, Inge ^a   hemel, Johan Van ^b   Vandenkerckhove, Jan ^b   Peys, Eric ^b   Sas, Benedikt ^b   Clercq, Erik De ^a   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Kemin Industries Inc   (United States)

Author keywords

Antiviral; Artemisinin; HCV; Hemin; Replicon

Indexed keywords

ARTEMISININ; HEMIN; RNA POLYMERASE; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; HEPATITIS C VIRUS; HOST CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REPLICON; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIMALARIALS; ARTEMISININS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HEMIN; HEPACIVIRUS; HUMANS; INHIBITORY CONCENTRATION 50; REPLICON; SESQUITERPENES; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 33746813574     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.07.014     Document Type: Article

References (39)

1. Lindenbach B.D., and Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 436 (2005) 933-938
2. Zoulim F., Chevallier M., Maynard M., and Trepo C. Clinical consequences of hepatitis C virus infection. Rev. Med. Virol. 13 (2003) 57-68
3. Anonymous, Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium, J. Viral. Hepat. 6 (1999) 35-47.
4. Craxi A., and Licata A. Clinical trial results of peginterferons in combination with ribavirin. Semin. Liver Dis. 23 Suppl. 1 (2003) 35-46
5. Klayman D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 228 (1985) 1049-1055
6. Tan R.X., Zheng W.F., and Tang H.Q. Biologically active substances from the genus Artemisia. Planta Med. 64 (1998) 295-302
7. Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist. Updat. 8 (2005) 85-97
8. Efferth T., Sauerbrey A., Olbrich A., Gebhart E., Rauch P., Weber H.O., Hengstler J.G., Halatsch M.E., Volm M., Tew K.D., Ross D.D., and Funk J.O. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 64 (2003) 382-394
9. O'Neill P.M., and Posner G.H. A medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. 47 (2004) 2945-2964
10. Parapini S., Basilico N., Mondani M., Olliaro P., Taramelli D., and Monti D. Evidence that haem iron in the malaria parasite is not needed for the antimalarial effects of artemisinin. FEBS Lett. 575 (2004) 91-94
11. Pandey A.V., Tekwani B.L., Singh R.L., and Chauhan V.S. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J. Biol. Chem. 274 (1999) 19383-19388
12. Eckstein-Ludwig U., Webb R.J., Van Goethem I.D., East J.M., Lee A.G., Kimura M., O'Neill P.M., Bray P.G., Ward S.A., and Krishna S. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424 (2003) 957-961
13. Ekthawatchai S., Kamchonwongpaisan S., Kongsaeree P., Tarnchompoo B., Thebtaranonth Y., and Yuthavong Y. C-16 artemisinin derivatives and their antimalarial and cytotoxic activities: syntheses of artemisinin monomers, dimers, trimers, and tetramers by nucleophilic additions to artemisitene. J. Med. Chem. 44 (2001) 4688-4695
14. Lee C.H., Hong H., Shin J., Jung M., Shin I., Yoon J., and Lee W. NMR studies on novel antitumor drug candidates, deoxoartemisinin and carboxypropyldeoxoartemisinin. Biochem. Biophys. Res. Commun. 274 (2000) 359-369
15. Hofheinz W., Burgin H., Gocke E., Jaquet C., Masciadri R., Schmid G., Stohler H., and Urwyler H. Ro 42-1611 (arteflene), a new effective antimalarial: chemical structure and biological activity. Trop. Med. Parasitol. 45 (1994) 261-265
16. Efferth T., Marschall M., Wang X., Huong S.M., Hauber I., Olbrich A., Kronschnabl M., Stamminger T., and Huang E.S. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J. Mol. Med. 80 (2002) 233-242
17. Kaptein S.J., Efferth T., Leis M., Rechter S., Auerochs S., Kalmer M., Bruggeman C.A., Vink C., Stamminger T., and Marschall M. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res. 69 (2006) 60-69
18. Romero M.R., Efferth T., Serrano M.A., Castano B., Macias R.I., Briz O., and Marin J.J. Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an in vitro replicative system. Antiviral Res. 68 (2005) 75-83
19. Smith S.L., Fishwick J., McLean W.G., Edwards G., and Ward S.A. Enhanced in vitro neurotoxicity of artemisinin derivatives in the presence of haemin. Biochem. Pharmacol. 53 (1997) 5-10
20. Smith S.L., Maggs J.L., Edwards G., Ward S.A., Park B.K., and McLean W.G. The role of iron in neurotoxicity: a study of novel antimalarial drugs. Neurotoxicology 19 (1998) 557-559
21. Van Thiel D.H., Friedlander L., Fagiuoli S., Wright H.I., Irish W., and Gavaler J.S. Response to interferon alpha therapy is influenced by the iron content of the liver. J. Hepatol. 20 (1994) 410-415
22. Hezode C., Cazeneuve C., Coue O., Roudot-Thoraval F., Lonjon I., Bastie A., Duvoux C., Pawlotsky J.M., Zafrani E.S., Amselem S., and Dhumeaux D. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J. Hepatol. 31 (1999) 979-984
23. Andant C., Lamoril J., Edery J., et al. Hepatic iron concentration (HIC) and serum iron parameters in patients with chronic hepatitis C. Hepatology 9 (1996) 497-503
24. Fillebeen C., Rivas-Estilla A.M., Bisaillon M., Ponka P., Muckenthaler M., Hentze M.W., Koromilas A.E., and Pantopoulos K. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J. Biol. Chem. 280 (2005) 9049-9057
25. Carroll S.S., Tomassini J.E., Bosserman M., Getty K., Stahlhut M.W., Eldrup A.B., Bhat B., Hall D., Simcoe A.L., LaFemina R., Rutkowski C.A., Wolanski B., Yang Z., Migliaccio G., De-Francesco R., Kuo L.C., MacCoss M., and Olsen D.B. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 278 (2003) 11979-11984
26. Vrolijk J.M., Kaul A., Hansen B.E., Lohmann V., Haagmans B.L., Schalm S.W., and Bartenschlager R. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J. Virol. Methods 110 (2003) 201-209
27. Lohmann V., Korner F., Dobierzewska A., and Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75 (2001) 1437-1449
28. Blight K.J., McKeating J.A., and Rice C.M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76 (2002) 13001-13014
29. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., and Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999) 110-113
30. Windisch M.P., Frese M., Kaul A., Trippler M., Lohmann V., and Bartenschlager R. Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J. Virol. 79 (2005) 13778-13793
31. Prichard M.N., and Shipman Jr. C. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14 (1990) 181-205
32. B. Sas, J. Van hemel, J. Vandenkerckhove, E. Peys, Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus (2005) US20050059647 A1.
33. Choi J., Lee K.J., Zheng Y., Yamaga A.K., Lai M.M., and Ou J.H. Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology 39 (2004) 81-89
34. Gong G., Waris G., Tanveer R., and Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc. Natl. Acad. Sci. USA 98 (2001) 9599-9604
35. Waris G., Tardif K.D., and Siddiqui A. Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF-kappaB and STAT-3. Biochem. Pharmacol. 64 (2002) 1425-1430
36. Waris G., Livolsi A., Imbert V., Peyron J.F., and Siddiqui A. Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease. J. Biol. Chem. 278 (2003) 40778-40787
37. Pietschmann T., Lohmann V., Rutter G., Kurpanek K., and Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75 (2001) 1252-1264
38. Stuyver L.J., McBrayer T.R., Tharnish P.M., Hassan A.E., Chu C.K., Pankiewicz K.W., Watanabe K.A., Schinazi R.F., and Otto M.J. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J. Virol. 77 (2003) 10689-10694
39. Silva I.S., Perez R.M., Oliveira P.V., Cantagalo M.I., Dantas E., Sisti C., Figueiredo-Mendes C., Lanzoni V.P., Silva A.E., and Ferraz M.L. Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study. J. Gastroenterol. Hepatol. 20 (2005) 243-248